Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
Conditions
Acute Biphenotypic Leukemia · Acute Myeloid Leukemia · Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Blasts 10 Percent or More of Bone Marrow Nucleated Cells · Blasts 10 Percent or More of Peripheral Blood White Cells · de Novo Myelodysplastic Syndrome · Myelodysplastic Syndrome · Previously Treated Myelodysplastic Syndrome · Recurrent Acute Myeloid Leukemia · Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Refractory Acute Myeloid Leukemia · Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Secondary Acute Myeloid Leukemia · Untreated Adult Acute Myeloid Leukemia
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
M D Anderson Cancer Center, Houston, Texas, United States
Contact: Principal Investigator (Tapan M. Kadia)
Study leads
Tapan M Kadia
Principal Investigator
M.D. Anderson Cancer Center